WuXi Biologics (Cayman) revenue and financials
In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +16.68%
- 2025 vs 2024
- Net income growth
- +46.25%
- 2025 vs 2024
- Net margin
- 22.5%
- 2024: 18.0%
How WuXi Biologics (Cayman) is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 31.2% a year on average over the last 5 years
Compound annual growth rate: from ¥5.61B in 2020 to ¥21.79B in 2025.
Revenue has grown for 9 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin rose from 28.5% to 30.5%
Operating income over revenue, 2022 → 2025: 2.0 percentage points.
Less cash than profit: free cash flow equal to 39% of net income
Totals for fiscal years 2023–2025: free cash flow ¥4.57B, net income ¥11.66B.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 21,790 | 18,675 | 17,034 | 15,269 | 10,290 | 5,612 | 3,984 | 2,534 | 1,619 | 989 |
| Cost of revenue | 11,772 | 11,025 | 10,206 | 8,545 | 5,461 | 3,079 | 2,325 | 1,517 | 958 | 600 |
| Gross profit | 10,019 | 7,651 | 6,828 | 6,724 | 4,829 | 2,533 | 1,659 | 1,018 | 661 | 389 |
| Selling, general and administrative | 2,519 | 2,299 | 2,086 | 1,693 | 1,133 | 722 | 451 | 326 | 175 | 110 |
| Research and development | 853 | 766 | 786 | 683 | 502 | 304 | 260 | 169 | 74.5 | 53.3 |
| Operating income | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 | 1,502 | 948 | 522 | 411 | 226 |
| EBIT | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 | 1,502 | 948 | 522 | 411 | 226 |
| EBITDA | 7,925 | 5,849 | 4,928 | 5,069 | 3,622 | 1,771 | 1,141 | 664 | 498 | 319 |
| Interest expense | 143 | 158 | 158 | 64.4 | 39.2 | 42.7 | 19.6 | — | 35.7 | 24.2 |
| Pre-tax income | 7,257 | 4,834 | 4,174 | 5,358 | 3,993 | 1,966 | 1,127 | 738 | 304 | 176 |
| Income tax | 1,524 | 889 | 603 | 808 | 485 | 273 | 116 | 107 | 51.1 | 34.8 |
| Net income | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 | 1,689 | 1,014 | 631 | 253 | 141 |
| Net income to common shareholders | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 | 1,689 | 1,014 | 631 | 253 | 141 |
| Basic EPS | 1.22 | 0.82 | 0.82 | 1.06 | 0.81 | 0.43 | 0.27 | 0.17 | 0.08 | 0.05 |
| Diluted EPS | 1.16 | 0.78 | 0.77 | 1.01 | 0.77 | 0.40 | 0.25 | 0.16 | 0.07 | 0.05 |
| Average shares (basic) | 4,027 | 4,082 | 4,164 | 4,173 | 4,174 | 3,953 | 3,717 | 3,632 | 3,222 | 2,892 |
| Average shares (diluted) | 4,176 | 4,227 | 4,349 | 4,376 | 4,422 | 4,209 | 3,997 | 3,942 | 3,481 | 2,892 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 11,787 | 11,837 | 9,953 | 10,101 | 8,574 | 8,542 | 8,492 | 8,062 | 7,206 | 5,883 |
| Cost of revenue | 6,339 | 6,071 | 5,700 | 5,800 | 5,224 | 5,275 | 4,931 | 4,751 | 3,793 | 3,351 |
| Gross profit | 5,448 | 5,766 | 4,253 | 4,301 | 3,350 | 3,267 | 3,561 | 3,311 | 3,413 | 2,532 |
| Selling, general and administrative | 1,183 | 1,262 | 1,051 | 1,151 | 996 | 1,004 | 785 | 845 | 587 | 593 |
| Research and development | 430 | 510 | 344 | 422 | 344 | 444 | 341 | 412 | 271 | 386 |
| Operating income | 3,728 | 3,922 | 2,724 | 2,766 | 1,820 | 1,630 | 2,302 | 1,866 | 2,484 | 1,530 |
| EBIT | 3,728 | 3,922 | 2,724 | 2,766 | 1,820 | 1,630 | 2,302 | 1,866 | 2,484 | 1,530 |
| EBITDA | 4,546 | 4,476 | 3,449 | 3,356 | 2,493 | 2,075 | 2,853 | 2,167 | 2,902 | 1,697 |
| Interest expense | 44.6 | 59.5 | 83.5 | 89.5 | 68.1 | 79.7 | 78.8 | 41.7 | 22.7 | 18.3 |
| Pre-tax income | 3,419 | 3,929 | 3,328 | 2,826 | 2,008 | 1,645 | 2,529 | 2,428 | 2,930 | 1,935 |
| Income tax | 503 | 952 | 571 | 661 | 228 | 412 | 191 | 499 | 309 | 309 |
| Net income | 2,440 | 2,569 | 2,339 | 1,857 | 1,499 | 1,133 | 2,267 | 1,885 | 2,535 | 1,546 |
| Net income to common shareholders | 2,440 | 2,569 | 2,339 | 1,857 | 1,499 | 1,133 | 2,267 | 1,885 | 2,535 | 1,546 |
| Basic EPS | 0.60 | 0.64 | 0.58 | 0.46 | 0.37 | 0.27 | 0.55 | 0.45 | 0.61 | 0.37 |
| Diluted EPS | 0.58 | 0.61 | 0.55 | 0.44 | 0.35 | 0.25 | 0.52 | 0.43 | 0.58 | 0.35 |
| Average shares (basic) | 4,097 | 4,029 | 4,026 | 4,061 | 4,103 | 4,169 | 4,158 | 4,170 | 4,176 | 4,198 |
| Average shares (diluted) | 4,181 | 4,166 | 4,186 | 4,198 | 4,256 | 4,348 | 4,350 | 4,365 | 4,386 | 4,436 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 63,697 | 56,977 | 56,576 | 49,564 | 44,033 | 28,964 | 17,602 | 9,393 | 4,849 | 1,985 |
| Current assets | 28,135 | 23,573 | 21,198 | 18,470 | 19,530 | 14,204 | 9,672 | 5,745 | 3,033 | 830 |
| Cash and equivalents | 9,214 | 8,279 | 9,670 | 6,395 | 9,003 | 7,096 | 6,205 | 4,084 | 504 | 169 |
| Short-term investments | 5,587 | 1,907 | 340 | 304 | 1,148 | 1,272 | 458 | — | 915 | — |
| Receivables | 8,896 | 6,374 | 6,675 | 5,775 | 4,181 | 2,770 | 1,665 | 995 | 493 | 377 |
| Inventory | 1,381 | 1,522 | 1,766 | 2,281 | 1,687 | 1,084 | 399 | 227 | 338 | 202 |
| Net property, plant and equipment | 29,754 | 28,435 | 29,939 | 25,916 | 19,756 | 12,870 | 6,796 | 2,904 | 1,780 | 1,153 |
| Goodwill | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 | 185 | 185 | — | — | — |
| Other intangible assets | 467 | 442 | 512 | 549 | 601 | 392 | 416 | 332 | — | — |
| Long-term investments | 3,203 | 2,400 | 2,934 | 2,709 | 2,203 | 1,074 | 452 | 192 | — | — |
| Current liabilities | 8,308 | 8,621 | 7,636 | 9,319 | 8,256 | 4,498 | 2,871 | 1,319 | 798 | 801 |
| Accounts payable | 1,092 | 747 | 833 | 1,221 | 618 | 646 | 186 | 221 | 137 | 105 |
| Long-term debt | 169 | 201 | 1,571 | 1,462 | 641 | 1,838 | 1,395 | — | — | 866 |
| Total debt | 3,104 | 4,940 | 4,561 | 4,422 | 4,295 | 3,332 | 2,194 | — | — | 946 |
| Total liabilities | 10,657 | 11,500 | 12,558 | 13,351 | 11,326 | 8,064 | 4,706 | 1,399 | 825 | 1,715 |
| Total equity (incl. minority) | 53,039 | 45,478 | 44,018 | 36,213 | 32,706 | 20,899 | 12,896 | 7,994 | 4,024 | 270 |
| Retained earnings | 23,242 | 18,334 | 14,978 | 11,578 | 7,158 | 3,769 | 2,080 | 1,069 | 446 | 194 |
| Minority interest | 5,791 | 3,658 | 3,686 | 1,166 | 428 | 335 | 112 | 0.5 | — | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 65,363 | 63,697 | 60,437 | 56,977 | 56,106 | 56,576 | 52,141 | 49,564 | 47,473 | 44,033 |
| Current assets | 27,197 | 28,135 | 24,447 | 23,573 | 19,817 | 21,198 | 17,878 | 18,470 | 20,657 | 19,530 |
| Cash and equivalents | 8,904 | 9,214 | 8,439 | 8,279 | 9,154 | 9,670 | 7,355 | 6,395 | 8,135 | 9,003 |
| Short-term investments | 3,521 | 5,587 | 3,158 | 1,907 | 340 | 340 | 248 | 304 | 336 | 1,148 |
| Receivables | 8,567 | 8,896 | 7,821 | 6,374 | 6,802 | 6,675 | 5,858 | 5,775 | 6,045 | 4,181 |
| Inventory | 1,758 | 1,381 | 1,655 | 1,522 | 1,963 | 1,766 | 1,965 | 2,281 | 2,144 | 1,687 |
| Net property, plant and equipment | 31,562 | 29,754 | 30,175 | 28,435 | 30,776 | 29,939 | 28,995 | 25,916 | 21,846 | 19,756 |
| Goodwill | 2,576 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 | 1,530 |
| Other intangible assets | 504 | 467 | 441 | 442 | 475 | 512 | 544 | 549 | 564 | 601 |
| Long-term investments | 3,031 | 3,203 | 3,007 | 2,400 | 2,808 | 2,934 | 2,760 | 2,709 | 2,431 | 2,203 |
| Current liabilities | 8,190 | 8,308 | 8,487 | 8,621 | 6,808 | 7,636 | 8,141 | 9,319 | 8,996 | 8,256 |
| Accounts payable | 1,367 | 1,092 | 969 | 747 | 875 | 833 | 573 | 1,221 | 995 | 618 |
| Long-term debt | 450 | 169 | 185 | 201 | 1,264 | 1,571 | 1,659 | 1,462 | 532 | 641 |
| Total debt | 2,726 | 3,104 | 5,107 | 4,940 | 4,567 | 4,561 | 5,141 | 4,422 | 4,399 | 4,295 |
| Total liabilities | 10,842 | 10,657 | 11,372 | 11,500 | 11,465 | 12,558 | 13,097 | 13,351 | 11,993 | 11,326 |
| Total equity (incl. minority) | 54,521 | 53,039 | 49,065 | 45,478 | 44,641 | 44,018 | 39,044 | 36,213 | 35,481 | 32,706 |
| Retained earnings | 25,682 | 23,242 | 20,673 | 18,334 | 16,477 | 14,978 | — | 11,578 | 9,693 | 7,158 |
| Minority interest | 6,450 | 5,791 | 4,113 | 3,658 | 3,986 | 3,686 | 1,306 | 1,166 | 1,019 | 428 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 6,341 | 5,217 | 4,668 | 5,542 | 3,431 | 1,881 | 1,208 | 762 | 360 | 81.9 |
| Depreciation and amortization | 1,448 | 1,437 | 1,169 | 801 | 482 | 303 | 221 | 142 | 87.5 | 93.2 |
| Capital expenditure | -3,685 | -3,930 | -4,046 | -5,868 | -6,508 | -6,025 | -3,211 | -1,341 | -671 | -429 |
| Investing cash flow | -3,087 | -3,942 | -3,228 | -5,908 | -9,602 | -7,216 | -4,494 | -416 | -2,213 | -421 |
| Financing cash flow | -2,164 | -2,750 | 1,961 | -2,592 | 8,209 | 6,566 | 5,413 | 3,207 | 2,229 | 333 |
| Share repurchases | -1,577 | -1,766 | -917 | -2,804 | -2,517 | — | — | — | — | — |
| Debt issued | 1,122 | 1,129 | 1,097 | 2,389 | 675 | 1,171 | 2,050 | — | 402 | 1,094 |
| Debt repaid | -2,901 | -819 | -1,916 | -2,684 | -822 | -350 | -162 | — | -1,488 | -481 |
| Effect of exchange rates | -155 | 84.0 | -126 | 350 | -132 | -340 | -5.9 | 28.2 | -41.6 | 17.3 |
| Net change in cash | 935 | -1,391 | 3,275 | -2,608 | 1,908 | 890 | 2,121 | 3,581 | 335 | 10.9 |
| Free cash flow | 2,656 | 1,288 | 622 | -327 | -3,077 | — | — | — | — | — |
| Levered free cash flow | 4,284 | -2,296 | -320 | -594 | -3,720 | -5,981 | -2,440 | -1,239 | -382 | -559 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4,287 | 4,534 | 1,807 | 3,915 | 1,302 | 1,918 | 2,750 | 4,084 | 1,458 | 2,633 |
| Depreciation and amortization | 937 | 594 | 854 | 613 | 824 | 501 | 668 | 300 | 501 | 150 |
| Capital expenditure | -2,757 | -1,785 | -1,900 | -2,062 | -1,867 | -1,664 | -2,381 | -3,184 | -2,685 | -2,435 |
| Investing cash flow | -2,138 | -2,549 | -538 | -3,559 | -383 | -1,639 | -1,589 | -3,545 | -2,363 | -1,860 |
| Financing cash flow | -2,111 | -1,078 | -1,086 | -1,275 | -1,476 | 2,149 | -188 | -2,373 | -219 | -3,006 |
| Share repurchases | -1,021 | -545 | -1,032 | -532 | -1,234 | -917 | — | -2,113 | -691 | -2,517 |
| Debt issued | 95.0 | 160 | 962 | 762 | 367 | 319 | 779 | 1,975 | 414 | 25.0 |
| Debt repaid | -911 | -1,941 | -960 | -382 | -436 | -1,014 | -901 | -2,259 | -425 | -499 |
| Effect of exchange rates | -302 | -132 | -23.1 | 44.3 | 39.7 | -113 | -13.0 | 94.3 | 256 | -45.3 |
| Net change in cash | -264 | 775 | 160 | -874 | -516 | 2,315 | 960 | -1,740 | -868 | -2,278 |
| Free cash flow | 1,530 | 2,749 | -93.7 | 1,853 | -565 | 253 | 369 | 900 | -1,227 | 199 |
| Levered free cash flow | -333 | 2,753 | 1,531 | -1,523 | -774 | -169 | -151 | 1,348 | -1,943 | 625 |
Financial statements of similar companies
Companies in the group: same industry, similar size
